Trials
2 active
2 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CX11 tablets administered orally once daily (QD) with high fat, high calorie meal”In the company’s words, NCT07652047 on ClinicalTrials.gov
- Tested for
- Type II Diabetes Mellitus, Obesity & Overweight
- Main trialPhase 2
- “This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days. The study is being done at multiple medical centers. Participants are assigned by chance (randomized) to different groups, and neither the participants nor the study staff know which group they're in (double-blind). The groups are compared side by side (parallel), and some participants will receive inactive pills…”In the company’s words, NCT07340320 on ClinicalTrials.gov
Other drugs for Type II Diabetes Mellitus
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- CagriSemaNovo Nordisk · Phase 3
- QLG1091Qilu Pharmaceutical · Phase 3
- SHR-3167Hengrui · Phase 3
- Maridebart cafraglutideAmgen · Phase 3
- LenbelintideAstraZeneca · Phase 3
Coming up2
- Mar 2027Phase 1 trial completes · ClinicalTrials.gov
- 8 Apr 2027Phase 2 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 10 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT07340320
- 10 NovCompletion date moved: 2027-04-16 to 2027-04-08 · ClinicalTrials.gov NCT07340320
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 8 Apr 2027 | A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus | |
| Phase 1Recruiting | Mar 2027 | A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026